Exact Sciences (EXAS) Tops Q4 EPS by 27c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. MSFT
4. JNJ
5. PLTR
6. META
7. QQQ
8. LDOS
9. HUM
10. CSCO

Go back to Exact Sciences (EXAS) Tops Q4 EPS by 27c, Offers Guidance

Exact Sciences Announces Fourth Quarter 2024 Results

February 19, 2025 4:05 PM EST

Fourth quarter and 2024 highlights

Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Total 2024 revenue of $2.76 billion, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $2.10 billion and Precision Oncology revenue of $655 million Plans to launch three new cancer tests in 2025: Cologuard Plus, next-generation colorectal cancer screening test, Oncodetect, molecular residual disease test, and Cancerguard, multi-cancer screening test

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq:... More